Apgdi patents expiration
1. Myrbetriq patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6346532 | APGDI | Amide derivatives or salts thereof |
Mar, 2022
(2 years ago) | |
| US7342117 | APGDI | α-form or β-form crystal of acetanilide derivative |
Nov, 2023
(5 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6699503 | APGDI | Hydrogel-forming sustained-release preparation |
Sep, 2013
(10 years ago) | |
| US6562375 | APGDI | Stable pharmaceutical composition for oral use |
Aug, 2020
(3 years ago) | |
|
US6346532 (Pediatric) | APGDI | Amide derivatives or salts thereof |
Sep, 2022
(1 year, 6 months ago) | |
| US8835474 | APGDI | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
Nov, 2023
(5 months ago) | |
| USRE44872 | APGDI | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
Nov, 2023
(5 months ago) | |
| US7982049 | APGDI | α-form or β-form crystal of acetanilide derivative |
Nov, 2023
(5 months ago) | |
| US7750029 | APGDI | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
Dec, 2023
(4 months ago) | |
|
US7342117 (Pediatric) | APGDI | α-form or β-form crystal of acetanilide derivative |
May, 2024
(14 days from now) | |
|
US7982049 (Pediatric) | APGDI | α-form or β-form crystal of acetanilide derivative |
May, 2024
(14 days from now) | |
|
US8835474 (Pediatric) | APGDI | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
May, 2024
(14 days from now) | |
|
USRE44872 (Pediatric) | APGDI | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
May, 2024
(14 days from now) | |
| US8772315 | APGDI | Pharmaceutical composition for treating overactive bladder |
Oct, 2028
(4 years from now) | |
|
US8772315 (Pediatric) | APGDI | Pharmaceutical composition for treating overactive bladder |
Apr, 2029
(5 years from now) | |
| US11707451 | APGDI | Pharmaceutical composition for modified release |
Sep, 2029
(5 years from now) | |
| US10842780 | APGDI | Pharmaceutical composition for modified release |
Sep, 2029
(5 years from now) | |
|
US10842780 (Pediatric) | APGDI | Pharmaceutical composition for modified release |
Mar, 2030
(5 years from now) | |
|
US11707451 (Pediatric) | APGDI | Pharmaceutical composition for modified release |
Mar, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-855) | Mar 25, 2024 |
| Pediatric Exclusivity(PED) | Sep 25, 2024 |
| New Indication(I-777) | Apr 27, 2021 |
| New Chemical Entity Exclusivity(NCE) | Jun 28, 2017 |
Drugs and Companies using MIRABEGRON ingredient
NCE-1 date: 26 September, 2023
Market Authorisation Date: 28 June, 2012
Treatment: For the treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency; Treatment of overactive bladder with symptoms of urge urinary incontinence, ur...
Dosage: TABLET, EXTENDED RELEASE;ORAL
MYRBETRIQ family patents
2. Myrbetriq Granules patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6346532 | APGDI | Amide derivatives or salts thereof |
Mar, 2022
(2 years ago) | |
| US7342117 | APGDI | α-form or β-form crystal of acetanilide derivative |
Nov, 2023
(5 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6346532 (Pediatric) | APGDI | Amide derivatives or salts thereof |
Sep, 2022
(1 year, 6 months ago) | |
| US7982049 | APGDI | α-form or β-form crystal of acetanilide derivative |
Nov, 2023
(5 months ago) | |
|
US7342117 (Pediatric) | APGDI | α-form or β-form crystal of acetanilide derivative |
May, 2024
(14 days from now) | |
|
US7982049 (Pediatric) | APGDI | α-form or β-form crystal of acetanilide derivative |
May, 2024
(14 days from now) | |
| US10058536 | APGDI | Pharmaceutical composition containing mirabegron |
Mar, 2036
(11 years from now) | |
|
US10058536 (Pediatric) | APGDI | Pharmaceutical composition containing mirabegron |
Oct, 2036
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 25, 2024 |
| Pediatric Exclusivity(PED) | Sep 25, 2024 |
Drugs and Companies using MIRABEGRON ingredient
Market Authorisation Date: 25 March, 2021
Treatment: Treatment of neurogenic detrusor overactivity (ndo) in pediatric patients aged 3 years and older by administration of an extended-release suspension formulation of mirabegron
Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL
MYRBETRIQ GRANULES family patents